Latest News on PTGX

Financial News Based On Company


Advertisement
Advertisement

Form 4 Protagonist Therapeutics Inc: Arturo MD Molina (Chief Medical Officer) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-protagonist-therapeutics-inc-arturo-md-molina-chief-medical-officer-for-16-november-93CH-5711235
This article reports on a Form 4 filing for Protagonist Therapeutics Inc, indicating an insider transaction by Arturo MD Molina, the Chief Medical Officer. The filing pertains to activity on November 16. The brief announcement provides no further details beyond the executive's name and the company involved.

Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells $338,798.70 in Stock

https://www.marketbeat.com/instant-alerts/insider-protagonist-therapeutics-nasdaq-ptgx-insider-sells-33879870-in-stock-2026-11-17/
Protagonist Therapeutics insider Arturo Molina sold 2,718 shares of PTGX stock for $338,798.70 to cover tax withholding obligations related to vested equity awards, reducing his stake by 3.23%. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Analysts currently maintain a consensus "Buy" rating for Protagonist Therapeutics with an average price target of $166.67.

Protagonist CEO Dinesh Patel Says ICOTYDE's 60,000 Prescriptions Mean No Equity Raise — and a $300 Million Buyback

https://finance.biggo.com/news/85ed3953d1fc2677
Protagonist Therapeutics CEO Dinesh Patel announced at the Jefferies Global Healthcare Conference that the company will not need an equity raise due to robust royalties from Johnson & Johnson's ICOTYDE psoriasis drug. The company plans a $300 million share buyback, indicating a shift in the biotech business model where value is captured at the point of partnership. Patel highlighted ICOTYDE's rapid launch with over 60,000 prescriptions and outlined Protagonist's pipeline, including an oral IL-17 inhibitor and an oral-only obesity portfolio, which are being funded by the successful partnership.

PTGX: Partnered launches fund a growing oral peptide pipeline, with key decisions due in 2027

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4659159:0-ptgx-partnered-launches-fund-a-growing-oral-peptide-pipeline-with-key-decisions-due-in-2027/
Protagonist Therapeutics (PTGX) has seen strong launches for ICOTYDE and MIMRYLO, with the latter receiving NCCN Category 1 guidance. The company is prioritizing its oral IL-17 and obesity peptides pipeline, with key development decisions and potential partnerships anticipated in 2027. This information is based on an audio transcript from the Jefferies Global Healthcare Conference on November 17, 2026.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Lowered by Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-protagonist-therapeutics-nasdaq-ptgx-stock-rating-lowered-by-wall-street-zen-2026-11-15/
Wall Street Zen has downgraded Protagonist Therapeutics (NASDAQ:PTGX) from a "strong buy" to a "buy" rating, though broader analyst sentiment remains largely positive with a consensus price target of $166.67. The company recently surpassed quarterly expectations, reporting EPS of $3.07 and revenue of $274.41 million. Despite these positive financials, company insiders have sold a significant number of shares totaling approximately $26.6 million over the past three months.
Advertisement

Protagonist Therapeutics, Inc. $PTGX Stock: Pictet Asset Management Holding SA Lowers Stake

https://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-stock-pictet-asset-management-holding-sa-lowers-stake-2026-11-10/
Pictet Asset Management Holding SA reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 16.9% in the third quarter, while other institutional investors like BlackRock Inc. and Johnson & Johnson increased their positions. Analyst sentiment remains largely positive, with a "Buy" average rating and an average price target of $166.67. The company recently reported strong quarterly earnings, beating analyst expectations for both EPS and revenue.

Wall Street Zen Upgrades Protagonist Therapeutics (NASDAQ:PTGX) to "Strong-Buy"

https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-protagonist-therapeutics-nasdaq-ptgx-to-strong-buy-2026-11-07/
Wall Street Zen has upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "Strong-Buy" rating, aligning with an overall "Buy" consensus and an average price target of $166.67 from analysts. The company surpassed quarterly earnings expectations, reporting an EPS of $3.07 and revenue of $274.41 million. Despite insider sales of approximately $41.4 million in shares over the past 90 days, the stock opened at $132.04.

A $39.3M year-earlier loss gives way to a Q3 profit at Protagonist Therapeutics (PTGX).

https://www.stocktitan.net/sec-filings/PTGX/10-q-protagonist-therapeutics-inc-quarterly-earnings-report-3258db44987b.html
Protagonist Therapeutics (PTGX) reported a significant financial turnaround in Q3 2026, earning $220.0 million in net income compared to a $39.3 million loss in the prior year. This profit surge was primarily driven by $274.4 million in license and collaboration revenue, largely due to opt-out and milestone payments from the Takeda Collaboration Agreement for MIMRYLO. The company also saw increased cash reserves and continues to advance its pipeline programs like PN-881, PN-477, and PN-8047, with several clinical trials anticipated in early 2027.

Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.dispatch.com/press-release/story/263070/protagonist-reports-third-quarter-2026-financial-results-and-provides-corporate-update/
Protagonist Therapeutics announced its Q3 2026 financial results, highlighting the FDA approval of MIMRYLO™ (rusfertide) for polycythemia vera, which triggered $275 million in payments. The company also reported strong commercial progress for ICOTYDE® (icotrokinra) and revealed plans to initiate a comprehensive Phase 2b program for PN-881 in early Q1 2027. Protagonist reported cash, cash equivalents, and marketable securities of $834.6 million as of September 30, 2026, and is executing a $300 million share repurchase program.

FDA approval of MIMRYLO triggers payments to Protagonist Therapeutics (PTGX).

https://www.stocktitan.net/sec-filings/PTGX/8-k-protagonist-therapeutics-inc-reports-material-event-896f041b3645.html
Protagonist Therapeutics announced that the FDA approval of MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to the company. This approval follows a strong third quarter for Protagonist, which reported $274.410 million in license and collaboration revenue and $220.015 million in net income. The company also initiated a $300 million share repurchase program and provided updates on other clinical programs.
Advertisement

Form 8K Protagonist Therapeutics Inc For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-protagonist-therapeutics-inc-for-5-november-93CH-5684870
This article announces the filing of a Form 8K by Protagonist Therapeutics Inc. for November 5. The content is concise, primarily serving as a notification of the regulatory filing, with no further details provided within the body. It also lists the stock symbol PTGX with a reported -5.66% change.

Protagonist Therapeutics (PTGX) Could Be 18% Undervalued As Earnings Expectations Rise

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-18-undervalued-as-ear
Protagonist Therapeutics (PTGX) is approaching its quarterly report with high expectations for earnings and revenue growth, despite recent short-term stock volatility. The company is currently considered 18% undervalued based on its fair value of $174.69 against a last close of $143.37, driven by potential in its oral peptide programs and existing approved assets. However, its high P/E ratio of 111.9x compared to industry averages suggests less room for error in its upcoming performance.

Polycythemia Vera Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therape

https://www.streetinsider.com/GetNews/Polycythemia+Vera+Pipeline+2026%3A+MOA+and+ROA+Insights%2C+Clinical+Trials+Status%2C+and+Key+Companies+Involved+by+DelveInsight+%7C+Roche%2C+Fujifilm+Holdings+Corp%2C+Hangzhou+Bensheng+Pharma%2C+Protagonist+Therape/27282091.html
A new report by DelveInsight provides a comprehensive assessment of the Polycythemia Vera (PV) pipeline in 2026, highlighting over 20 companies developing more than 25 treatment therapies. Key emerging therapies include rusfertide (approved by the FDA in August 2026), givinostat, bomedemstat, and SLN124, with significant clinical trial advancements in 2026. The report details the mechanisms of action, routes of administration, and identifies market drivers such as unmet medical needs and novel therapeutic approaches, alongside challenges like complex pathophysiology and clinical trial hurdles.

UBS reiterates Buy on Protagonist Therapeutics stock citing Mimrylo launch progress

https://ca.investing.com/news/stock-market-news/ubs-reiterates-buy-on-protagonist-therapeutics-stock-citing-mimrylo-launch-progress-93CH-4924490
UBS has reiterated a Buy rating and an $184.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) following positive insights regarding the launch progress of its drug Mimrylo. The drug, partnered with Takeda, received FDA approval for treating erythrocytosis in adults with polycythemia vera and is seeing favorable adoption among specialists. Despite a significant stock surge and some overvaluation according to InvestingPro data, analysts anticipate strong sales growth for the current year.

(PTGX) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/52/PTGX_as_a_Liquidity_Pulse_for_Institutional_Tactics_110326042801_1793698081.html
This article provides an institutional-grade analysis of Protagonist Therapeutics Inc. (NASDAQ: PTGX), highlighting a strong near-term sentiment shifting towards a long-term positive bias. It details an exceptional 41.3:1 risk-reward setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The analysis emphasizes real-time entry/exit signals, risk-reward ratios, and comprehensive risk management.
Advertisement

TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $160

https://www.moomoo.com/news/post/1001878006/td-cowen-maintains-protagonist-therapeutics-ptgxus-with-buy-rating-raises
TD Cowen has reaffirmed its "Buy" rating on Protagonist Therapeutics (PTGX.US) stock. The firm also increased its price target for the company from $68 to $160. This reflects a significant positive outlook on the biopharmaceutical company.

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

https://www.dispatch.com/press-release/story/258718/protagonist-therapeutics-to-participate-in-four-investment-bank-conferences-in-november-2026/
Protagonist Therapeutics announced that its senior management will participate in four investment bank conferences in November 2026, including the Wolfe Research Healthcare, Truist Securities Biopharma, UBS Global Biopharma, and Jefferies Global Healthcare conferences. The company will engage in fireside chats and one-on-one meetings to discuss its pipeline, which includes two FDA-approved medicines, ICOTYDE™ and MIMRYLO™. These conferences will take place in New York and London, offering opportunities for investors to meet with the Protagonist team.

Protagonist Therapeutics, Inc. (PTGX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/PTGX/seasonality/
This article provides a seasonal returns chart for Protagonist Therapeutics, Inc. (PTGX), showing average monthly price returns from 2016 to 2026. The stock's current price and after-hours trading information are also displayed, along with links to other financial data.

Protagonist Therapeutics (PTGX) Is Back In The Spotlight, What Is Catching Attention?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-is-back-in-the-spotlight-what
Protagonist Therapeutics (PTGX) is gaining attention as analysts have collectively raised earnings per share estimates, signaling changing expectations for its pipeline and funding. The company's stock has seen significant growth in 2026, with a 63.04% year-to-date return and an 82.58% one-year return. Despite being considered 19% undervalued with a fair value of $174.69, the stock trades at a high P/E ratio of 110.9x, suggesting potential valuation risk if sentiment shifts.

Protagonist Therapeutics (PTGX) Projected to Announce Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-protagonist-therapeutics-ptgx-projected-to-announce-earnings-on-thursday-2026-10-29/
Protagonist Therapeutics (PTGX) is expected to announce its Q3 2026 earnings after market close on Thursday, November 5th, with analysts forecasting earnings of $2.50 per share and revenue of $238.49 million. The company exceeded expectations in its previous quarter, reporting $2.29 EPS and $213.47 million in revenue, a significant year-over-year increase. Despite a consensus "Buy" rating and a $163.27 price target from analysts, insiders have sold approximately $41.4 million worth of stock over the last 90 days.
Advertisement

BlackRock amends its Protagonist Therapeutics (PTGX) stake disclosure, naming an iShares ETF with over 5%.

https://www.stocktitan.net/sec-filings/PTGX/schedule-13g-a-protagonist-therapeutics-inc-amended-passive-investmen-b2df8146e084.html
BlackRock, Inc. has filed an Amendment No. 8 for its beneficial ownership of Protagonist Therapeutics (PTGX), reporting a 15.2% stake, or 9,834,146 common shares. The filing specifies that BlackRock holds sole voting power over 9,719,796 shares and sole dispositive power over all 9,834,146 shares. Additionally, the iShares Core S&P Small-Cap ETF is identified as having an interest exceeding 5% of Protagonist's outstanding common stock.

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

https://www.tradingview.com/news/acceswire:39a8aa510094b:0-protagonist-therapeutics-to-participate-in-four-investment-bank-conferences-in-november-2026/
Protagonist Therapeutics (PTGX) announced that senior management will participate in four investment bank conferences in November 2026, including the Wolfe Research Healthcare Conference, Truist Securities Biopharma Symposium, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference. The company will engage in fireside chats and one-on-one meetings with investors at these events. A replay of presentations will be available on their Investor Relations webpage.

10,448 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Robeco Institutional Asset Management B.V.

https://www.marketbeat.com/instant-alerts/filing-10448-shares-in-protagonist-therapeutics-inc-ptgx-purchased-by-robeco-institutional-asset-management-bv-2026-10-27/
Robeco Institutional Asset Management B.V. acquired 10,448 shares of Protagonist Therapeutics (NASDAQ:PTGX) in Q3, valued at approximately $1.47 million. Institutional investors now own 98.63% of the company, and analysts generally maintain a "Buy" rating with an average target price of $158.19. Despite strong quarterly results and significant revenue growth, insiders have sold approximately $41.4 million in shares over the past 90 days.

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

https://www.desmoinesregister.com/press-release/story/144394/protagonist-therapeutics-to-participate-in-four-investment-bank-conferences-in-november-2026/
Protagonist Therapeutics announced its senior management will participate in four investment bank conferences in November 2026, including events hosted by Wolfe Research, Truist Securities, UBS, and Jefferies. The conferences will feature fireside chats and one-on-one meetings. The company also highlighted its FDA-approved medicines, ICOTYDE™ and MIMRYLO™, and its pipeline of clinical and preclinical programs.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Average Target Price of $158.19 According to Analysts

https://www.marketbeat.com/instant-alerts/consensus-protagonist-therapeutics-inc-nasdaq-ptgx-stock-has-average-target-price-of-15819-according-to-analysts-2026-10-27/
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has received a consensus "Buy" rating from analysts, with an average 12-month price target of $158.19. The company recently surpassed quarterly earnings and revenue expectations, and institutional ownership remains high, though insiders have been selling shares. Several firms, including Goldman Sachs and Wedbush, have reiterated or raised their price targets for PTGX.
Advertisement

Protagonist Therapeutics, Inc. Estimates – NASDAQ:PTGX

https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-estimates/
This article provides an overview of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) financial data and analyst estimates available on TradingView. It highlights sections for income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

TD Cowen maintains Buy rating on Protagonist Therapeutics, $160 price target

https://www.tradingview.com/news/tradingview:d8bcb3e199c23:0-td-cowen-maintains-buy-rating-on-protagonist-therapeutics-160-price-target/
TD Cowen has reaffirmed its Buy rating on Protagonist Therapeutics (PTGX), setting a price target of $160.00, which suggests a 16.0% upside from its recent closing price. The analyst note highlights the company's strong clinical pipeline, including promising candidates like rusfertide and icotrokinra, and its innovative approach to peptide-based therapeutics for various medical needs.

Protagonist Therapeutics (PTGX) Wins FDA Nod for MIMRYLO and a $275 Million Milestone

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-wins-fda-nod-for-mimrylo-and-a
Protagonist Therapeutics (PTGX) received FDA approval for MIMRYLO (rusfertide) to treat polycythemia vera, triggering a $275 million milestone payment from Takeda and converting MIMRYLO into a royalty-generating product. This approval is expected to shift Protagonist Therapeutics towards a more commercially anchored model, funding its oral peptide pipeline through recurring royalties and milestones rather than equity raises. Investors are now watching Takeda's real-world prescribing of MIMRYLO and progress on other pipeline assets like PN-881 and PN-477 to assess future revenue breadth.

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

https://www.tradingview.com/news/prnewswire:621ab0bb024a8:0-a-phase-3-win-and-a-130-takeover-premium-lit-up-rare-blood-disease-stocks-on-monday/
Two significant announcements on Monday boosted rare blood-disease stocks. Disc Medicine reported successful Phase 3 trial results for its light-sensitivity disorder treatment, causing shares to jump 38.86%. Concurrently, Silence Therapeutics agreed to be acquired by Merck KGaA at a 130% premium, leading to a 125.58% surge in its shares.

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

https://thegleaner.com/press-release/story/4260/protagonist-announces-new-icotrokinra-data-in-ulcerative-colitis-showing-potential-for-a-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill/
Protagonist Therapeutics has announced positive Week 12 results from its Phase 2b ANTHEM-UC study of icotrokinra, an oral peptide for moderately to severely active ulcerative colitis. The study met its primary endpoint, showing significant clinical response and improvement in secondary endpoints across all dose groups compared to placebo, with a favorable safety profile. These results support the initiation of a registrational Phase 3 study in ulcerative colitis and a Phase 2b/3 study in Crohn's disease, highlighting icotrokinra's potential as a new oral treatment option.
Advertisement

Protagonist Therapeutics, Inc. (PTGX) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_6315_QuantitativeReport_1790726400000
Argus has lowered its target price for Protagonist Therapeutics Inc. (PTGX) to $148.00 from its current price of $128.75. Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel constrained peptide-based drug candidates.

Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September By Investing.com

https://za.investing.com/news/stock-market-news/form-4-protagonist-therapeutics-inc-asif-ali-cfo-for-30-september-93CH-4510084
This article reports on a Form 4 filing for Protagonist Therapeutics Inc, specifically detailing an insider transaction by Asif Ali, the company's CFO, for September 30. Form 4 filings are regulatory documents that disclose changes in the ownership of securities by a company's officers, directors, and principal stockholders. The information is provided by Investing.com, a financial markets news source.

Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September

https://ng.investing.com/news/stock-market-news/form-4-protagonist-therapeutics-inc-asif-ali-cfo-for-30-september-93CH-2741912
This article reports on a Form 4 filing for Protagonist Therapeutics Inc., specifically detailing insider transactions by Asif Ali, the company's CFO, for the period ending September 30. Form 4 filings are legally required disclosures of changes in beneficial ownership of securities by a company's officers, directors, or principal stockholders. The article highlights that the stock symbol PTGX saw a gain of 2.64%.

Form 4 Protagonist Therapeutics Inc: Asif Ali (CFO) For: 30 September

https://in.investing.com/news/stock-market-news/form-4-protagonist-therapeutics-inc-asif-ali-cfo-for-30-september-93CH-5638745
This article reports on a Form 4 filing for Protagonist Therapeutics Inc., specifically noting a transaction by CFO Asif Ali related to September 30. The piece includes the stock symbol PTGX, which was down 5.71% at the time of publication. The core content is the announcement of this financial filing, with no further details provided in the article itself.

Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-protagonist-therapeutics-nasdaq-ptgx-raised-to-strong-buy-at-zacks-research-2026-10-16/
Zacks Research has upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "strong buy" rating, joining other analysts who maintain a bullish outlook with a consensus "buy" rating and an average price target of $154.44. The company recently surpassed quarterly earnings and revenue estimates, reporting $2.29 EPS and $213.47 million in revenue. Despite recent insider sales totaling approximately $41.4 million, institutional investors and hedge funds hold a significant 98.63% stake in the company.
Advertisement

Citi keeps Buy rating for Protagonist Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/citi-keeps-buy-rating-for-protagonist-therapeutics-stock/70334673
Citi has reiterated its Buy rating for Protagonist Therapeutics (PTGX) stock, setting a price target of USD 182.00. This follows a strong second quarter in 2026 where the company reported USD 213.48 million in revenue and USD 162.85 million in net income, a significant improvement from the previous year. Investors are now looking to the upcoming earnings report on November 5, 2026, to see if this revenue trend will continue.

Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today

https://www.benzinga.com/news/26/10/62383644/here-s-how-much-100-invested-protagonist-therapeutics-10-years-ago-would-be-worth-today
Protagonist Therapeutics (NASDAQ: PTGX) has significantly outperformed the market over the last decade, with an annualized return of 19.88%. An initial investment of $100 in PTGX 10 years ago would now be valued at $612.94. This illustrates the substantial impact of compounded returns on wealth growth over time.

Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-21-undervalued-as-roy
Protagonist Therapeutics (PTGX) shares closed at US$138.49, showing positive momentum year-to-date and over the past year. Analysts suggest the stock is 21% undervalued, with a fair value of $174.69, driven by its royalty-funded pipeline and strong cash position. However, a different valuation method using the P/E ratio indicates the stock is demanding at 108.1x compared to peers.

Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group

https://www.marketbeat.com/instant-alerts/analyst-protagonist-therapeutics-nasdaq-ptgx-raised-to-strong-buy-at-ubs-group-2026-10-14/
UBS Group upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "strong-buy" rating. This upgrade comes as other analysts, including Leerink Partners and Citigroup, have also raised their price targets for the company. Despite recent insider selling, institutional investors maintain a significant stake in Protagonist Therapeutics, which recently exceeded quarterly earnings and revenue expectations with substantial year-over-year growth.

UBS sets USD 184.00 target for Protagonist Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/ubs-sets-usd-184-00-target-for-protagonist-therapeutics-stock/70319035
UBS initiated coverage on Protagonist Therapeutics (PTGX) with a Buy rating and a USD 184.00 price target on October 12, 2026. This target is based on the commercial potential of PN-881 and possible royalty revisions for Mimrylo, with UBS's 2027 and 2028 estimates significantly above consensus. The company reported strong second-quarter revenues of USD 213.47 million and diluted earnings per share of USD 2.29, supporting the positive outlook from analysts.
Advertisement

(PTGX) Movement as an Input in Quant Signal Sets

https://news.stocktradersdaily.com/news_release/8/PTGX_Movement_as_an_Input_in_Quant_Signal_Sets_101326072002_1791933602.html
This article from Stock Traders Daily discusses Protagonist Therapeutics Inc. (NASDAQ: PTGX), highlighting a strong near-term sentiment that could lead to a long-term positive bias. It presents three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels for the stock.

Protagonist Therapeutics Initiated at Buy by UBS

https://www.moomoo.com/news/post/1000941553/protagonist-therapeutics-initiated-at-buy-by-ubs
UBS has initiated coverage on Protagonist Therapeutics with a "Buy" rating. This indicates a positive outlook from the investment bank regarding the company's stock. Investors may view this as a signal to consider buying shares of Protagonist Therapeutics.

PTGX Initiates Coverage On UBS -- Price Target Announced at $184

https://www.gurufocus.com/news/9119281/ptgx-initiates-coverage-on-ubs-price-target-announced-at-184
UBS has initiated coverage on Protagonist Therapeutics (PTGX) with a 'Buy' rating and a price target of $184.00, reflecting confidence in the company's biopharmaceutical innovations. Despite this positive analyst rating, GuruFocus indicates PTGX is currently 37.1% overvalued, with a GF Score™ of 58/100, and has seen significant insider selling. Investors are advised to approach PTGX with caution due to the overvaluation and mixed signals from guru and insider activities.

PTGX Assumes by Leerink Partners -- Price Target Raised to $190

https://www.gurufocus.com/news/9119162/ptgx-assumes-by-leerink-partners-price-target-raised-to-190
Leerink Partners has initiated coverage of Protagonist Therapeutics (PTGX) with an "Outperform" rating, raising its price target to $190, signaling strong confidence in the company's growth potential. Despite this optimistic analyst outlook, GuruFocus assesses PTGX as 32.8% overvalued with a GF Value™ of $108.27, and highlights concerns regarding its high P/E ratio, moderate GF Score™ of 58/100, and notable insider selling. Investors are advised to consider both the positive analyst sentiment and the valuation concerns.

UBS initiates Protagonist Therapeutics stock with buy rating on drug potential

https://ng.investing.com/news/stock-market-news/ubs-initiates-protagonist-therapeutics-stock-with-buy-rating-on-drug-potential-93CH-2730838
UBS has initiated coverage on Protagonist Therapeutics Inc. (NASDAQ: PTGX) with a buy rating and a price target of $184.00, citing the strong potential of its drug pipeline, particularly PN-881. This bullish outlook follows recent FDA approvals for Mimrylo and Icotyde, leading to increased price targets from several other analysts and a forecast of $2.9 billion in peak sales for Mimrylo by 2036. The stock is currently trading at $143.73, up significantly year-to-date.
Advertisement

UBS initiates Protagonist Therapeutics stock with buy rating on drug potential

https://www.investing.com/news/analyst-ratings/ubs-initiates-protagonist-therapeutics-stock-with-buy-rating-on-drug-potential-93CH-4943273
UBS has initiated coverage on Protagonist Therapeutics Inc. (NASDAQ:PTGX) with a buy rating and a price target of $184.00, citing the potential of its pipeline drugs, especially PN-881, and expected upward revisions to Mimrylo royalty estimates. This positive outlook follows recent FDA approvals for Mimrylo and Icotyde, which have also led other analysts to raise their price targets and maintain buy ratings for the company. The stock currently trades at $143.73, showing a significant year-to-date increase.

UBS initiates Protagonist Therapeutics stock with buy rating on drug potential

https://ca.investing.com/news/stock-market-news/ubs-initiates-protagonist-therapeutics-stock-with-buy-rating-on-drug-potential-93CH-4875190
UBS has initiated coverage on Protagonist Therapeutics Inc. (NASDAQ:PTGX) with a buy rating and a price target of $184.00, citing the potential of its drug pipeline, particularly PN-881 ("oral Bimzelx"). The bullish outlook is further supported by recent FDA approval of Mimrylo and several analysts raising their price targets for the company. InvestingPro data, however, suggests the stock might be overvalued relative to its Fair Value estimate despite a 64.56% year-to-date increase.

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-protagonist-therapeutics-nasdaq-ptgx-stock-rating-cut-to-buy-at-wall-street-zen-2026-10-10/
Protagonist Therapeutics (NASDAQ:PTGX) had its stock rating cut from "strong buy" to "buy" by Wall Street Zen, although the consensus among 17 other analysts remains favorable with a "Buy" rating and a target price of $147.13. The company recently reported strong quarterly EPS of $2.29, beating estimates, and revenue of $213.47 million, a significant year-over-year increase. Despite insider stock sales totaling approximately $41.4 million in the last three months, institutional investors hold 98.63% of the company, with BlackRock and Johnson & Johnson making substantial recent investments.

Protagonist Therapeutics stock fell 1.38 percent on October 6

https://www.ad-hoc-news.de/boerse/news/nebenwerte/protagonist-therapeutics-stock-fell-1-38-percent-on-october-6/70247145
Protagonist Therapeutics (PTGX) stock dropped 1.38% on October 6, 2026, closing at USD 138.69 on Nasdaq. Despite the dip, analysts maintain a "Strong Buy" consensus with an average 12-month price target of USD 174.69, significantly above its current trading price and reflecting optimism following strong Q2 2026 earnings. The company's next earnings report is scheduled for November 5, 2026, which will be a key indicator for its ability to sustain growth and reach analyst targets.

Protagonist Therapeutics stock gains 1.47 percent on Nasdaq 2026-10-05

https://www.ad-hoc-news.de/boerse/news/corporate-news/protagonist-therapeutics-stock-gains-1-47-percent-on-nasdaq-2026-10-05/70235640
Protagonist Therapeutics (PTGX) stock rose 1.47% on Nasdaq on October 5, 2026, closing at USD 142.12. This increase follows strong Q2 2026 earnings, where revenue reached USD 213.47 million and EPS beat consensus estimates. The company also announced a USD 300 million share repurchase program and holds a "Moderate Buy" consensus rating from analysts.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement